Reduction in blood glucose values following indomethacin therapy for patent ductus arteriosus.
OBJECTIVE
To evaluate the effects of indomethacin on blood glucose values in premature infants with patent ductus arteriosus (PDA).


METHODS
Twenty-five very low birthweight infants with PDA were given 0.2 mg/kg, i.v., indomethacin for up to three doses. We examined the relationship between blood glucose values and glucose infusion rate before and after indomethacin therapy.


RESULTS
There was a significant reduction in blood glucose values between 12 and 96 h following i.v. indomethacin therapy. Eleven of 25 infants (44%) had blood glucose values below 40 mg/dL between 12 and 60 h (mean 32.7 h) after the initial dose. Although the glucose infusion rate during the first 12 h was constant (3.56 +/- 0.98 mg/kg per min), the blood glucose values decreased from 96 +/- 32 mg/dL at the starting point to 75 +/- 29 mg/dL at 12 h (P < 0.05). The maximum blood glucose reduction was 51.6 +/- 34.7 mg/dL and the maximum blood glucose reduction rate was 50.4 +/- 20.2%.


CONCLUSIONS
The results suggest that blood glucose values should be measured at least every 6 h for 72 h until they stabilize in order to prevent unexpected hypoglycemia.
Hosono
S
S
Division of Neonatology, Saitama Children's Medical Center, Japan. hosonos@rb3.so-net.ne.jp
Ohno
T
T
Kimoto
H
H
Nagoshi
R
R
Shimizu
M
M
Nozawa
M
M
D002317:Cardiovascular Agents / Q000009:adverse effects*; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007213:Indomethacin / Q000009:adverse effects*; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D008297:Male; D012189:Retrospective Studies; D018709:Statistics, Nonparametric
D002317:Cardiovascular Agents; D007213:Indomethacin